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Abstract
ESKAPE pathogens are notorious in causing nosocomial infections and escaping current
antibiotic treatments. There has been a dramatic increase in nosocomial infections accompanied
with a decrease in the number of antibiotics developed, leading to significant increase in morbidity
and mortality among patients. In an attempt to combat this problem, derivatives of ciprofloxacin,
rifabutin and beta-lactam antibiotics were synthesized and tested against the ESKAPE pathogens.
From minimum inhibitory concentration assays, 4 ciprofloxacin analogs and 8 beta-lactam analogs
were found to be effective against multiple bacterial species. Additionally, 12 rifabutin analogs
and 23 beta-lactam analogs were potent against single bacterial species, primarily toward
methicillin-resistant Staphylococcus aureus (MRSA) at a concentration of ≤ 25 µg mL-1. Based on
the effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), three rifabutin
analogs were selected for further testing. Two rifabutin analogs (DU644 and DU645) were found
to possess between a one to twofold mean increase of inhibitory activities, while the other rifabutin
analogs (DU650) demonstrated up to a twofold decrease of inhibitory activity when compared to
the parent drug. These compounds were then examined for their bactericidal and antibiofilm
activities against MRSA. From these assays, we found that DU644 and DU645 were 4 times more
bactericidal and antibiofilm against MRSA when compared to the parent drug. In addition, rpoB
mutation validation results confirmed that modification of these rifabutin derivatives at the C-3
and C-4 positions, and bearing an imidazolyl ring carrying substituted spiropiperidyl ring, did not
change their mechanism of action towards the beta-subunit of RNA polymerase. Cytotoxicity
v

testing performed using human hepatocellular carcinoma epithelial cells (hepG2) showed that at
concentrations ranged from 1.25 µg mL-1 to 25 µg mL-1, DU644 and DU645 showed very low
toxicity. Collectively, structural drugs modifications of these obsolete drugs are able to restore
their antibacterial activities against MRSA, which is notable as the most infectious nosocomial
pathogen. Therefore, further development and application of rifabutin analogs might be beneficial
for medical use to combat MRSA infections.
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Chapter One: Introduction

Nosocomial infections play a pivotal role in increasing large numbers of illnesses and death
among patients (Hsueh, 2002). About 2 million people in US hospitals become ill as a result of
these infections, resulting in nearly 100,000 deaths every year (Klevens et al., 2007). Therefore,
these infections have become a prominent public health problem that needs to be addressed.
The acronym of ESKAPE pathogens (coined by the Infectious Disease Society of
America), represents six drug-resistant bacterial species, Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species. The members of this group are capable of resisting current antibiotics and
have become the leading causes of nosocomial infections in United States hospitals (Rice, 2008).
The number of patients that die from methicillin-resistant Staphylococcus aureus infections
(MRSA), for example, exceeds those who die of HIV/AIDS in US hospitals (Boucher and Corey,
2008). In addition to this, as cited from the National Nosocomial Infections Surveillance System
Report CDC 2004, extremely resistant Acinetobacter strains, multi-drug resistant P. aeruginosa,
and carbapenem-resistant Klebsiella species are rapidly emerging, and are a major concern not
only in United States, but also in other parts of the world (Boucher et al., 2009). Furthermore,
resistance toward the antibiotic of last resort, colistin, was reported among Enterobacteriacae,
primarily among Escherichia coli, and K. pneumoniae (Liu et., al,2016; Malhotra-Kumar et
al.,2016; McGann et., al, 2016). Most recently, in the United States, E. coli MRSN 388634 with
plasmid carrying mcr-1 gene resistance to colistin was reported, presaging the emergence of
1

extremely multidrug resistant bacteria (McGann et al. 2016). These findings indicate that we are
close to post antibiotic era, in which minor injuries and mild infections become deadly (WHO,
2015).
The discovery of penicillin unlocked the door of the golden era of antibiotic research from
the years 1940 to 1962, leading to the discovery of streptomycin, chloramphenicol, and
tetracycline (Singh and Barrett, 2006). These antibiotics vastly decreased the number of bacterial
diseases at that time, making this a triumph that was thought to be the end of bacterial disease
(Penesyan, Gillings, and Paulsen, 2015). However, soon after penicillin was prescribed as a
wonder drug that saved lives from threatening infections, bacterial resistance toward penicillin
emerged and therefore allowed bacteria to expand resistance toward other developed antibiotics.
In an effort to overcome these problems, scientists and pharmaceutical industries worked on
discovering and disseminating new classes of antibiotics (Ventola, 2015). Nevertheless, the belief
that the bacterial infection crisis was resolved, was abolished by emerging antibiotic resistance
cases reported afterward, such as Staphylococcus aureus resistant strains that were identified in
England in 1961; these strains were resistant to penicillin G, streptomycin, and tetracycline
(Jevons, 1961).
One of the reasons that bacteria can resist the antibacterial actions of these drugs is related
to their extraordinary adaptability to survive in all possible climates and conditions, even in very
harsh environments that cannot be occupied by human beings (Spellberg et al., 2008).
Furthermore, the replication process of bacteria can occur within 20-30 minutes, which allows
them to have a more rapid reproduction compared to other organisms. These abilities grant bacteria
the capacity to survive antibiotic treatment, and pass on resistance to their next generation.
Therefore, the problem of misusing antibiotics may not be the cornerstone of resistance

2

development, but rather it affects the speed in which bacteria develop resistance. Indeed, the
genetic analysis of microbial pathways revealed that bacteria acquired beta-lactamase enzymes to
withstand the effects of beta-lactam antibiotics more than 2 billion years ago, long before humans
discovered penicillin (Hall, Salipante, and Barlow, 2004). Obviously, the proper use of antibiotics
is very important to reduce selective pressures that could escalate the pace of resistance. This
necessitates the stable and rapid development of new antibiotics to answer the threats of drug
resistant bacteria.
Bacterial resistance toward antibiotics is mainly obtained either by genetic mutation or by
horizontal gene transfer. Genetic mutations result in reduced penetration of drugs (porins) (Low et
al., 2001), increased extrusion of drugs (efflux pumps) (Yan et al., 2006), target modification
(Nagai et al., 2002), and hydrolytic enzyme production (Linstrom, Boman, and Steele, 1970). In
addition to these, bacterial resistance is also acquired through mobile genetic elements, plasmids
and transposons, which can transfer new resistance genes to other bacteria and can cause multiple
resistance towards several antibiotics (Normark and Normark, 2002). The following is an
explanation of each bacterial resistance mechanism and genetic resistance transfer pathway:

Porin Mutations and Active Efflux Pumps
As is widely known, the bacterial outer membrane is the first protection against antibiotics.
The outer membrane of Gram-negative bacteria consists of a lipid bilayer that is not permeable to
large positively or negatively charged molecules. The first transport system for molecules entering
the membrane is that of influx, regulated by porins. The shift of porin expression during antibiotic
treatment points to bacterial adaptability towards drugs, which limits membrane permeability and
decreases the concentration of antibiotic that enters the cell (Low et al., 2001). The second
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transport system is that of bacterial protein export, used to extrude harmful substances such as
antibiotics out of the cell. This system is known as efflux, and can be overexpressed due to genetic
mutations within efflux genes and their regulatory elements (Yan et al., 2006). These extrusion
mechanisms can specifically export a particular substance or expel various substances such as
multiple antibiotics, leading to multidrug resistance (Webber, 2002). Broadly, multidrug resistance
mechanisms result from the decreased permeability of the membrane related to porin alteration
combined with efflux mechanisms (Hancock, 1998). Therefore, both influx and efflux, transport
systems of bacteria, are notable as conjoint factors that contribute to bacterial resistance against
antimicrobials.

Antibiotic Alteration and Target Modification
Antibiotic alteration and inactivation by bacterial enzymes are other examples of resistance
mechanisms. A classic example of alteration is the inactivation of beta-lactam molecules through
enzymatic hydrolysis by beta-lactamase enzymes, produced by resistant bacteria (D'Agata et al,.
1998), resulting in beta-lactam antibiotics losing their effectiveness. Another example is the
function of chloramphenicol acetyltransferases (CATs) that catalyze acetylation of
chloramphenicol, thereby inactivating antibacterial effects (Schwarz et al., 2004). Another
resistance mechanism performed by bacteria is target modification, where each antibiotic has a
specific target to bind, and the modification of the target abrogates the antibiotic’s activity (Nagai
et al., 2002).
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Horizontal Gene Transfer
In addition to the resistance mechanisms occurring as a result of genomic mutations,
horizontal gene transfer also contributes in generating bacterial resistance. This occurs through
transformation, transduction or conjugation. Transformation is the process by which the DNA of
one bacteria is taken up by another, while transduction is DNA transfer via phages (Davison,
1999). Conjugation, is the transfer of DNA through direct contact; in some bacteria this process
involves plasmids that play role in delivering multidrug resistance genes and increasing the
numbers of multidrug resistant bacteria (Poulin-Laprade, Carraro, and Burrus, 2015).
In the face of the swift increase of resistance among the ESKAPE pathogens, the decrease
in the pace of antibiotic development has also become problematic. The Infectious Diseases
Society of America (IDSA) discovered an abrupt 75% decline of FDA antibiotic approval between
1983 and 2007 (Boucher et al., 2009). In an effort to overcome these problems, a national and
global scale antibacterial research and development initiative was issued by the IDSA with the aim
to develop 10 new or modified antibiotics by the year 2020; this is known as the 10 x 20 initiative
(IDSA, 2010). To accelerate this commitment, USF scientists work together, discovering novel
antibacterials and modifying obsolete ones. Accordingly, structural drug modification of
ciprofloxacin, rifabutin, and beta-lactam antibiotics were performed in the course of our research
to increase their potential against the ESKAPE pathogens. Studies on structurally modified
ciprofloxacin, rifabutin, and beta-lactams that were previously performed become the foundation
of our studies and therefore will be discussed in this chapter.
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N-Acylated Ciprofloxacin
Fluoroquinolones are the most routinely prescribed drugs for adults in US, forming a large
and narrow spectrum of antibacterial agents (Linder et al., 2005). This class of antibiotics function
by binding to the type II topoisomerase, DNA gyrase, as well as topoisomerase IV; the enzymes
that mediate re-ligation and separation of double stranded DNA (Mustaev et al., 2014). Thus
fluoroquinolones inhibits DNA replication of bacteria (Becnel Boyd et al., 2008). The most widely
used fluoroquinolone is ciprofloxacin (Linder et al., 2005). However, its frequent use has led to
bacterial resistance, which occurs through many mechanisms, including trans-conjugated plasmids
(Cheung, 2005) or from chromosomal mutations that occur in the Quinolone Resistance
Determining Region of target genes (Yoshida et al., 1991) .
In order to increase the potential antibacterial activity of ciprofloxacin, and reduce
resistance, N-acylated ciprofloxacins have been synthesized by the addition of lipophilic acyl
residues toward the nitrogen atom of the piperazinyl ring (Cormier et al., 2012) Figure 1 displays
one of our N-acylated ciprofloxacin analogs that was tested against the ESKAPE pathogens.

Figure 1. Structural modification of ciprofloxacin. This figure displays a regular ciprofloxacin (i), and its
analog that was modified through the addition of acyl group at the nitrogen atom of the piperazinyl ring (ii).

A previous study conducted by Cormier et al. (2012) confirms that N-acylated
ciprofloxacins have more potent antibacterial activity than regular ciprofloxacin against
Staphylococcus aureus, Bacillus anthracis, Enterococcus faecalis, Bartonella species, and
6

Escherichia coli. The results of this investigation show that from eighteen derivatives tested, six
compounds were as active as ciprofloxacin in inhibiting methicillin-susceptible Staphylococcus
aureus (MSSA) at a concentration of 10 µg mL-1 and three derivatives inhibited MSSA at a
concentrations of < 10 µg mL-1. Moreover, the MIC of ciprofloxacin analogs toward B. henselae
was achieved at 0.2 µg mL-1, whilst that of the parental drug was 0.5 µg mL-1. In addition to this,
bacterial frequency mutations toward these derivatives was assessed through spontaneous
mutation assays, showing that at 2.5 x MIC, the three selected compounds produced no bacterial
growth recovery. Nevertheless, at a concentration of 1 x MIC, bacterial colonies were obtained.
Conversely, resistant colonies were found at 2.5 x MIC of ciprofloxacin. Biochemical examination
was performed to investigate the ability of these ciprofloxacin analogs to interfere with DNA
gyrase, revealing a stable action of the drug with this enzyme that obstructed its activity.
Furthermore, toxicity assays for all analogs using Saccharomyces cerevisiae showed no
detrimental effects on eukaryotic cells. Therefore, based on the results mentioned above, Nacylated ciprofloxacins have more effective antibacterial activity toward Gram-positive and Gramnegative bacteria than regular ciprofloxacin.

Rifabutin Analogs
Another widely used antibacterial agent, rifamycin, works by inhibiting DNA-dependent
RNA polymerase, hence preventing the initiation of transcription. One member of the rifamycin
family, rifabutin, possesses broad spectrum activity against Gram-positive and Gram-negative
bacteria (Kunin, 1996). In addition, rifabutin has potent activity as an anti-mycobacterial (Barrow
et al., 2015), and anti-staphylococcal agent in HIV/AIDS patients (Styrt, Chaisson, and Moore,
1997). Acquired resistance to rifamycins results from a mutation that occurs within the rpoB gene,
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which encodes the beta-subunit of the DNA-dependent RNA polymerase (Bodmer et al., 1995; Jin
& Gross, 1988). Some mutations present resistance to rifabutin alone, to other rifamycins, or to all
rifamycin family members (Williams et al., 1998). In an effort to restore antibacterial activity of
rifamycins, semisynthetic analogs were synthesized via the modification of C-3 and C-4 positions
into an imidazolyl ring, carrying a spiro-piperidyl group (Sanfilippo et al., 1980; Barluenga et al.,
2006). Figure 2 shows two of our rifabutin analogs that were modified at C-3 and C-4 positions,
carrying aromatic rings substituted with halogen elements.

Figure 2. Structural modification of rifabutin. This figure displays a regular rifabutin (i),
and its analogs that were modified at C-3 and C-4 positions into an imidazolyl ring carrying a
spiropiperidyl group (ii and iii).
Previous synthesized rifabutin derivatives were examined for their anti-mycobacterial
activity against susceptible and multidrug resistant strains of mycobacterium species (Garcia et al.
2010). It was found that at a concentration of ≤ 0.02 µg mL-1, two rifabutin analogs inhibited the
growth of rifabutin susceptible strains of M. tuberculosis, and at a concentration of ≤ 0.5 µg mL-1,
these analogs were able to inhibit the growth of multidrug-resistant strains. In contrast, the
susceptibility of these strains towards regular rifampin and rifabutin occurs at 50 µg mL-1 and 10
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µg mL-1, respectively. To find a rationale behind this significant deviation between bioactivity of
the rifabutin analogs and the parent drug toward multi-drug resistant tuberculosis (MDR-TB),
molecular dynamics calculations were performed. In doing so, it was determined that the newer
compounds have a stronger binding affinity to RNA polymerase in resistant strains. In addition,
toxicity tests conducted on bovine endothelial cells showed no harmful effects yielded by these
derivatives. In conclusion, rifabutin analogs have more potent anti-mycobacterial activity
compared to regular rifabutin, due to a stronger mode of action.

Beta-lactam Analogs
In the last 70 years, since the discovery of penicillin in 1940, beta-lactam antibiotics have
become the most common drugs used to treat bacterial infections. The mechanism of action of
beta-lactam antibiotics is to bind with penicillin binding proteins (PBPs) that function in bacterial
cell wall synthesis (Beadle, Nicholas, and Shoichet, 2001). The broad use of beta-lactams in the
treatment of bacterial infections has led to increased resistance of Gram-positive and Gramnegative bacteria toward these drugs; including Staphylococcus aureus (Zhang, 2001),
Pseudomonas aeruginosa (Van der Bij et al., 2011), Acinetobacter baumannii (Mera et al., 2010)
and Klebsiella pneumoniae (Palasubramaniam, Muniandy, and Navaratnam, 2009). Bacterial
resistance toward beta-lactams can be obtained through several ways: porin mutations (Fang et al.,
2014) and the activity of specific genes encoding multidrug efflux activity (Li, Nikaido, and Poole,
1995) that affect intrusion and extrusion of antibiotics, respectively. Moreover, bacterial betalactamase enzymes production can inactivate the drugs and cause multidrug resistance (Van der
Bij et al., 2011; Mahdian et al., 2015; Pollini et al., 2013; Caltagirone et al., 2015), which can be
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mediated by plasmids that transfer beta-lactamase resistance from one bacteria to another
(Caltagirone et al., 2015).

i

ii

Figure 3. Structural modification of beta-lactam. This figure displays a regular beta-lactam
(i), and its analog that was modified at C-3, C-4, and N-1 positions of the beta-lactam ring (ii).

Attempts to restore the effectiveness of beta-lactam antibiotics have been performed
through structural drug modifications. Turos et al. (2002) developed N-thiolated beta-lactams and
assessed their bioactivity against Gram-positive and Gram-negative bacteria. One of the Nthiolated beta-lactam derivatives developed by Dr. Turos, depicted in Figure 3, was screened
against the ESKAPE pathogens. Previous studies on the antibacterial activity of N-thiolated betalactams revealed their specificity against the growth of Gram-positive bacteria, especially
staphylococci (including MRSA), with lower MICs compared to that of penicillin. Specifically,
the most active beta-lactam derivatives inhibited the growth of MSSA at a concentration of 15 µg
mL-1, and MRSA strains at a concentration of 5-10 µg mL-1. These results are in contrast to
penicillin that was able to inhibit the growth of MRSA at a concentration exceeding 64 µg mL-1.
In addition, N-thiolated beta-lactams seemingly have a different mechanism of action compared
to regular beta-lactam, based on differential morphology of bacterial cells after treatment with the
analogues. Moreover, the effectiveness of N-thiolated derivatives examined by Turos et al. (2002)
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against MRSA indicated that they were able to escape the activity of beta-lactamase enzymes
produced by resistant bacteria. To continue exploring the mechanism of action of N-thiolated betalactams at a molecular level, further work by the Turos group demonstrated a direct interaction
between beta-lactam derivatives and co-enzyme A. Furthermore, these compounds significantly
disrupted fatty acid synthesis in bacteria, inhibiting lipid metabolism and impeding the growth of
bacteria (Revell et al., 2007). In addition to these findings, Prosen et al. (2011) also confirmed the
potent antibacterial activity of N-thiolated beta-lactams on Gram-positive bacteria, demonstrating
growth inhibition of MRSA at a concentration of 5 µg mL-1. This suggests that N-thiolated betalactam derivatives are a potent class of antibiotics, though their specific target pathway has yet to
be identified.

Project Aim
Literature reviews concerning the enhanced bioactivity of ciprofloxacin, rifabutin, and
beta-lactam analogs against resistant bacteria, and the urgent need to find treatments to solve the
problem of nosocomial infections, has inspired our research against the ESKAPE pathogens.
Specifically, this study aimed to determine if structural modifications of ciprofloxacin, rifabutin,
and beta-lactam antibiotics resulted in more potent antibacterial activities against the ESKAPE
pathogens compared to parent drugs. Assessments of antibacterial activities of these derivatives
performed to achieve this goal included minimum inhibitory concentration, bactericidal,
antibiofilm, spontaneous mutation, and target mutation validation.
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Chapter Two: Materials and Methods
Setting
This research was conducted from August 2015 to May 2016 at Shaw lab at the University
of South Florida. Here in Shaw lab, we focus on performing drug discovery to combat the
ESKAPE pathogens, and exploring disease-causing mechanisms of MRSA at the molecular level.
My research was to determine the antibacterial activity of novel variants of ciprofloxacin, rifabutin
and beta-lactams against the ESKAPE pathogens. Antibacterial assessments that I performed were
minimum inhibitory concentration, bactericidal, antibiofilm, spontaneous mutation, and target
mutation validation. Moreover, cytotoxicity assessment was also conducted to determine toxicity
effect of our compounds toward human hepatocellular carcinoma epithelial cell (HepG2).
Ciprofloxacin and beta-lactam analogs were provided by our collaborators from Dr. Turos
laboratory at the University of South Florida, whilst rifabutin analogs came from Dr. Maria-Paz
Cabal at Instituto Universitario de Quımica, Spain.

Materials
Bacterial Strains:
Enterococcus faecium strain 1449
Methicillin-resistant Staphylococcus aureus strain 635
Klebsiella pneumoniae strain 1433
Acinetobacter baumannii strain 1403
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Pseudomonas aeruginosa strain 1419
Enterobacter cloacae strain 1454

Primer Sequences
OL1524 R rpoB (TAA TAG CCG CAC CAG AAT CA)
OL1525 F rpoB (GTG TAA AAG TGC GTC TAA TC)

Tryptic Soy Broth (TSB)
3% tryptic soy

Tryptic Soy Agar (TSA)
3% tryptic soy
1.5% agar

Mueller Hinton Broth (MHBI)
2.2% Mueller Hinton

Biofilm Media
3% sodium chloride (NaCl)
3% tryptic soy
0.5% dextrose (C6H12O6)
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Bacterial Growth Media
All media for culturing bacteria were prepared using deionized water and sterilized using
an autoclave. In particular, Gram-positive bacteria were grown in 5 mL of TSB, whilst Gramnegative bacteria were grown in MHBI. The overnight culture of bacteria were performed in 5 mL
of TSB or MHBI for 24 hours at 37 °C in a shaking incubator. TSA was prepared to allow for
bacterial recovery after being exposed to compounds, thus the number of bacteria colonies could
be counted. Biofilm media was utilized to perform biofilm assay.

Phosphate Buffered Saline (PBS)
0.14 % sodium phosphate dibasic anhydrous (Na2HPO4)
0.02% potassium chloride (KCl)
0.02% potassium phosphate monobasic anhydrous (KH2PO4)
0.8% sodium chloride (NaCl)

Buffer
Phosphate buffered saline (PBS) was prepared using deionized water, adjusted with 1 M
hydrochloric acid (HCl) to pH 7.4, and sterilized using an autoclave.

Methods
A key assessment of an antibacterial agent is to determine whether the compound inhibits
bacterial growth (bacteriostatic), or if it works by killing the bacteria (bactericidal). This is first
determined through a minimum inhibitory concentration (MIC) assay, the gold standard to test the
susceptibility of bacteria towards a compound (Andrews, 2001). In this assay, ranges of
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concentrations for a given compound were examined to find the lowest concentration required to
inhibit the growth of bacteria. Subsequently, minimum bactericidal concentration (MBC) assays
were conducted to determine the ability of lead compounds to completely terminate bacterial
viability. MIC and MBC protocols were carried as performed by Van Horn et al. (2014).

Minimum Inhibitory Concentration Assay (MIC)
Bacteria were grown in 5 mL of tryptic soy broth (TSB) for 24 hours in order to obtain a
large enough bacterial sample for MIC testing. After 24 hours at 37°C, Gram-positive and Gramnegative bacteria were diluted 1:1000 in fresh TSB or Mueller Hinton Broth (MHBI), respectively.
Following this, bacteria were transferred into 96 well plates and the compounds were added for a
total volume of 200 µL per well. Assays were conducted in triplicate for each concentration tested.
The plates were then incubated under static conditions for 24 hours at 37° C. The MIC value of
each compound was determined based on visual inspection (lack of turbidity) of the lowest
concentration that completely inhibited bacterial growth.

Minimum Bactericidal Concentration (MBC)
Following overnight incubation with compounds, samples were serially diluted from 10-1
to 10-7 in PBS and thereafter spot plated in duplicate onto TSA to obtain a countable number of
bacteria. Nutrient agar plates were incubated at 37°C for 24 hours. Following incubation, the
colony forming units (CFU) recovered on plates was calculated and converted to CFU mL-1 using
the dilution factor of the plate where the CFU were obtained. Subsequently, recovery of the
bacteria was determined by comparing the CFU mL-1 of the treatment group to the CFU mL-1 of
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the no drug control. The MBC of the lead agents were determined as the lowest concentration of
the agent that killed 99% of bacteria.

Antibiofilm Assay
The protocol for this assay was performed based on the experiment conducted by Fleeman
et al. (2015). Twenty percent human plasma was added to 96-well plates and incubated at 4°C
overnight. Next, overnight cultures of MRSA were grown in 5 mL of TSB at 37°C for 24 hours.
Following this, overnight cultures were standardized in fresh biofilm media to reach an optical
density (OD600) of 0.5. Thereafter, the human plasma was removed and 150 µL of the diluted
culture was added to the wells and incubated at 37°C for 24 hours. After incubation, the media
was carefully removed from the 96 well plate and replaced with fresh biofilm media combined
with the lead compounds and/or controls to a total volume of 200 µL per well. Each assay was
conducted in triplicate. Samples were incubated for 24 hours at 37°C before being processed. The
media was carefully removed from the wells without disturbing the biofilm and gently washed
three times with PBS to remove planktonic bacteria. After washing, the biofilms were resuspended
in 100 µL of sterile PBS by vigorous pipetting. The resuspended biofilm was then transferred into
a new 96-well plate and serially diluted as described above. Aliquots were plated onto nutrient
agar plates, and incubated at 37°C overnight. Bacterial colonies were counted, and the colony
forming unit CFU mL-1 was converted to percent recovery by comparison to no drug controls.

Bacterial Resistance Assay
Bacterial resistance assessment was performed using spontaneous mutations assays
described by Van Horn et al. (2014). MRSA overnight cultures were prepared as described above.
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Following this, TSA was prepared and mixed together with the selected compounds to generate
plates with 5 x MIC, 10 x MIC, 20 x MIC, or 50 x MIC. 1 mL of overnight cultures were pelleted
through centrifugation and resuspended in 100 µL of TSB media. The resuspended samples were
plated directly onto nutrient agar containing our lead compounds, and incubated overnight at 37°C.
The mutation frequency of bacteria for each compound was measured by dividing the number of
colonies on the plates with the total inoculum of bacteria (CFU mL-1 on no drug plates). The
concentration of the compounds was increased from the lower concentration (5 x MIC), to the
higher concentration (10 x, 20 x, or 50 x MIC) when the bacterial recovery was not enumerable
due to mutation rates that were too high. Each experiment was performed in triplicate.

rpoB Mutation Validation Assay
In order to ascertain whether or not our lead compounds employ the same mechanism of
action as the parent compound, mutant colonies from spontaneous mutation assays were randomly
selected, and their rpoB gene was sequenced and analyzed. Prior to the sequencing process, DNA
of the mutants were extracted based on Shaw lab’s S. aureus chromosomal DNA extraction
protocols. PCR product purification was performed using QIAquick PCR purification kit (Qiagen)
as described by the manufacturer’s protocols with the following modification.

DNA Extraction
Mutants from the spontaneous mutation assays were randomly selected, and grown in 5
mL TSB at 37°C, overnight. The overnight samples were centrifuged for 10 minutes and
resuspended in 600 µL TE buffer. Bacterial cultures were lysed using glass beads for 1 minute
using a Minibeadbeter Biospec. Samples were then centrifuged at full speed for 1 minute to remove
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precipitants, and the supernatants were transferred into new eppendorf tubes. To isolate the DNA
from protein contaminant, 200 µL of sarkosyl (1.6%) and 5 µL proteinase K were added into the
eppendorf tubes. The reactions were incubated at 60°C for 1 hour. Following incubation, 700 µL
phenol-chloroform was added into reactions and the samples were centrifuged at full speed for 1
minute; this was done to separate the remaining protein from DNA. The upper liquid layer of each
sample, containing DNA, was carefully transferred to a new eppendorf tube. Following this, the
DNA was precipitated by mixing the samples with 500 µL isopropanol and 100 µL of 3M sodium
acetate prior to overnight incubation at -80°C. Thereafter, samples were centrifuged at 13,000 x g
for 10 minutes and the supernatant was removed. To wash the DNA, 500 µL of 70% ethanol was
added to the pellet, and then samples were centrifuged at full speed for 5 minutes. After
centrifugation, the ethanol was discarded and the tubes were air dried at room temperature for 4
minutes. After the ethanol was completely removed from the tubes, 200 µL of RNA free water
was added into the tube and mixed with samples; the concentration of DNA was measured using
a Nanodrop ND-1000 spectrophotometer. DNA was then stored at 4°C for 24 hours.

PCR Purification
After storage, the concentrated DNA was diluted to 60 ng µL-1, while the master mix for
PCR reaction was prepared by mixing 20 µL of 2x phusion master mix with 20 µL RNA free
water. Subsequently, 1 µL of the diluted DNA, 1 µL of reverse (5′-GTG TAA AAG TGC GTC
TAA TC-3′) and forward primer (5′-TAA TAG CCG CAC CAG AAT CA-3′), and 17 µL of master
mix was mixed together in new PCR tubes. The samples were run on a Bio-Rad Thermal Cycler
for 2 hours. After that, gel electrophoresis was performed to confirm the size of the amplicon.
Furthermore, 100 µL phosphate buffer (PB) was added into the each PCR tube containing 20 µL
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of PCR product, samples were then transferred into spin columns and spun at 13,000 x g for 1
minute; for a total of three times. Subsequently, the liquid contained on the bottom of the tubes
was discarded, and the DNA retained on the columns was washed with 700 µL washing buffer (PE
buffer). The columns were centrifuged at full speed for 1 minute, and the liquid on the bottom of
the tubes was removed; to completely remove the ethanol from the column, they were re-spun at
full speed for 3 minutes. The columns were placed into a fresh eppendorf tube, and 30 µL of free
RNA water was pipetted onto the membrane of the columns. The tubes were incubated at room
temperature for 1 minute, and centrifuged at full speed for 1 minute. The liquid from the bottom
of the tubes was transferred back onto the membrane of the column and spun for 1 minute; this
step was repeated once. Next, the column was discarded, and the concentration of the DNA was
measured using a nanodrop spectrophotometer. Following the PCR purification process, the PCR
products were sent to Eurofins MWG Operon LLC, a Eurofins Genomic company for sequencing.
Nucleotides of the mutants were compared with those of the reference strain through NCBI blast
nucleotide and protein database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Protein sequencing
analysis was further conducted utilizing Pfam database (http://pfam.xfam.org/) to reveal the
location and type of amino acid change within the RpoB protein of the mutants

Cytotoxicity Assay
The protocol for this toxicity assay was performed based on the method of Fleeman et al.
(2015), with the following modifications. Human HepG2 cells were cultured in Dulbecco
Modified Eagle Medium (DMEM) containing L-glutamine, supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin, and incubated at 37°C incubator with 5% CO2 for 72 hours.
Cells were then diluted to 1.0 x 105 mL-1 in 96 well tissue culture plates (CellStar) at a total volume
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of 100 µL per well. After this, the diluted cells were incubated for 24 hours in a 37°C incubator
with 5% CO2. Following incubation, media was gently removed and replaced with fresh DMEM
supplemented with test compounds at a concentration of 1.5 to 50 µg mL-1. The cells were
incubated with compound for 2 days in a 37°C incubator with 5% CO2. Next, the media containing
compound was removed and substituted with media containing 3-(4,5- dimethylthiazol-2-yl)- 2,5diphenyltetrazolium bromide (MTT). The plates were then incubated for 4 hours, followed by the
removal and replacement of 50 µL of media with 100% dimethyl-sulfoxide (DMSO).
Subsequently, plates were incubated for 10 minutes at 37°C in order to dissolve the formazan
crystals produced. Formazan quantification was performed using a Synergy2 Biotek plate reader,
recording at 540 nm. The lethal dose (LD50) for each compound was determined by calculating the
compound concentration at which 50% of the cells were killed. The calculation for LD50 was based
on the derived linear regression equation as described by (Houard et al. 2013).
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Chapter Three: Results
Minimum Inhibitory Concentration Determination Assay (MIC)
In this study the antibacterial activity of the analogues of three classes of structurally
modified antibiotics, ciprofloxacin, rifabutin, and beta-lactams, were determined using a high
throughput phenotypic assay. The first approach employed as a preliminary drug assessment was
determination of the minimum inhibitory concentration (MIC) for 1,248 compounds against the
ESKAPE pathogens after 24 hours of incubation. From this high throughput screening, 4
ciprofloxacin analogs and 8 beta-lactam analogs were found to be active against multiple bacterial
species, whereas 12 rifabutin analogs and 23 beta-lactam analogs were found to be active against
a single bacterial species at a concentration of ≤ 25 µg mL-1.

MICs of Ciprofloxacin Analogs toward the ESKAPE Pathogens

The MIC values of ciprofloxacin analogs were determined for the four derivatives (Table
1), demonstrating activity against both Gram-positive and Gram-negative bacteria. Amongst these,
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DU008 displayed the best activity, resulting in complete inhibition of all Gram-positive species,
E. faecium and S. aureus (MRSA CBD-635), with an MIC achieved at 25 µg mL-1. In addition,
DU008 was also active against all Gram-negative bacteria, with MICs of 1 µg mL-1 for K.
pneumoniae, A. baumannii, and E. cloacae, and 5 µg mL-1 for P. aeruginosa. Likewise, compound
DU667 was active against E. faecium at a concentration of 5 µg mL-1, yet showed no inhibition
toward MRSA at a concentration of 100 µg mL-1. In addition, DU667 inhibited all Gram negative
species, with an MIC of 1 µg mL-1 for K. pneumoniae, 5 µg mL-1 for A. baumannii and E. cloacae,
and 10 µg mL-1 for P. aeruginosa. Similar to DU667, DU165 also possessed very low activity
against MRSA; nevertheless, it was active against E. faecium and all four Gram-negative bacteria.
The inhibitory activity of DU165 toward K. pneumoniae and E. cloacae was achieved at a
concentration of ≤ 5 µg mL-1, and for E. faecium, A. baumannii and P. aeruginosa at a
concentration of ≤ 25 µg mL-1. In contrast, DU632 was the least active compound amongst all
ciprofloxacin analogs, with inhibitory activity achieved at 100 µg mL-1 for E. faecium and A.
baumannii; however, DU632 displayed no activity against MRSA, K. pneumoniae, P. aeruginosa,
and E. cloacae at a concentration of 100 µg mL-1. Moreover, the regular ciprofloxacin was not
able to inhibit MRSA at a concentration of 100 µg mL-1; nevertheless, it was able to inhibit the
other ESKAPE pathogens with MIC values achieved at 100 µg mL-1. Figure 4 represents an
overview of bioactivity for all ciprofloxacin analogs. The scaled score for each compounds showed
that each of this ciprofloxacin analog has broad-spectrum activities toward Gram-positive bacteria,
primarily toward E. faecium, and toward all Gram-negative bacteria; however, DU632 showed no
inhibition toward K. pneumoniae, P. aeruginosa, and E. cloacae.
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Figure 4. Inhibitory activity of ciprofloxacin analogs. This graph displays the bioactivity of ciprofloxacin
analogs in inhibiting the growth of the ESKAPE pathogens and was made based on their MIC values that had
been converted into a scaled score. The scaled score was created by the equation; Scaled score = 100/MIC (µg
mL-1).

MICs of Rifabutin Analogs toward the ESKAPE Pathogens

Twelve rifabutin analogs were tested against the ESKAPE pathogens in this study and displayed
narrow inhibitory activity against MRSA (Table 2, Figure 5); four rifabutin analogs selectively inhibited
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MRSA at a concentration of ≤ 0.08 µg mL-1 (DU645, DU644, DU649, and DU650), while the other eight
analogs showed lower inhibitory activity with MICs achieved exceeding 0.16 µg mL-1. DU645 was the most
active MRSA inhibitor with MIC achieved at 0.02 µg mL-1. The other two active analogs, DU644 and
DU649, inhibited the growth of MRSA at a concentration of 0.04 µg mL-1; whilst the inhibitory activity of
DU650 was achieved at 0.08 µg mL-1. In contrast, rifabutin, displayed higher MIC value toward MRSA than
those of DU645, DU644, and DU649; rifabutin inhibited MRSA at a concentration of 0.05 µg mL-1.
Moreover, rifabutin was also active against another Gram-positive bacteria, E. faecium, and all Gran negative
species: K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae with MIC achieved at 0.4 µg mL-1,
12.5 µg mL-1, 3.125 µg mL-1, 12.500 µg mL-1, and 25 µg mL-1, respectively.
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Figure 5. Inhibitory activity of rifabutin analogs. This graph displays the bioactivity of rifabutin analogs in
inhibiting the growth of methicillin-resistant S. aureus (MRSA) and was made based on their MIC values that
had been converted into a scaled score. The scaled score was created by the equation; Scaled score = 100/MIC
(µg mL-1).

MICs of Beta-lactam Analogs toward the ESKAPE Pathogens
The MIC values of beta-lactam analogs against the ESKAPE pathogens demonstrated that
many of these analogs possessed a narrow spectrum of activity against Gram-positive bacteria,
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primarily MRSA, and some had wide antibacterial activities against E. faecium, MRSA, and Gramnegative bacteria, particularly K. pneumoniae, A. baumannii, and P. aeruginosa (Table 3, Table
4, Figure 6, Figure 7). Thirty-seven of 66 beta-lactam analogs showed narrow inhibition spectrum
toward MRSA with MIC of ≤ 100 µg mL-1. DU074 and DU100, for example, were active against
MRSA with an MIC was achieved at 1 µg mL-1 and 100 µg mL-1, respectively. Similarly, those
with broad-spectrum inhibition also had MICs of ≤ 100 µg mL-1 toward multiple pathogens.
DU1060, for example, inhibited the growth of E. faecium, MRSA, and A. baumannii at a
concentration of 25 µg mL-1, K. pneumoniae and P. aeruginosa at a concentration of 50 µg mL-1,
and E. cloacae at a concentration of 100 µg mL-1. DU1036, however, had a MIC of 5 µg mL-1 for
E. faecium and MRSA, and 25 µg mL-1 for A. baumannii. Conversely, the MICs of ampicillin, a
regular beta-lactam antibiotic, were achieved at higher concentrations than those of beta-lactam
analogs. Specifically, ampicillin had an MIC of 100 µg mL-1 for E. faecium, and showed no
discernable inhibitory activity for MRSA, P. aeruginosa, K. pneumoniae, A. baumannii, and E.
cloacae at a concentration of 100 µg mL-1.

Figure 6. Inhibitory activity of beta-lactam analogs. This graph displays the bioactivity of beta-lactam analogs
in inhibiting the growth of the ESKAPE pathogens, and was created based on their MIC values that had been
converted into a scaled score. The scaled score was composed by the equation; Scaled score = 100/MIC (µg mL1
).
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Figure 7. Inhibitory activity of beta-lactam analogs. This graph displays the bioactivity of beta-lactam analogs
in inhibiting the growth of the ESKAPE pathogens, and was created based on their MIC values that had been
converted into a scaled score. The scaled score was composed by the equation; Scaled score = 100/MIC (µg mL1
).
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From these high throughput screening results, we selected the three most active rifabutin
analogs that possessed activity against MRSA to further perform drug characterization through
minimum bactericidal concentration (MBC) determination, spontaneous mutation and rpoB
mutation validation, and eukaryotic cytotoxicity assessment.

Minimum Bactericidal Concentration Determination Assay (MBC99)
Determining the ability of the compounds in inhibiting bacterial growth (bacteriostatic), or
terminating bacterial viability (bactericidal) are necessary in drug characterization. Therefore, after
performing MIC testing, MBC assays were conducted to assess bactericidal activities of our
frontrunner compounds. MBC assay was performed for the most active rifabutin analogs, DU644,
DU645, and DU650, toward our clinical MRSA isolate. The MBC results on Figure 8 and Table
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6 suggest that all lead compounds possess potent bactericidal activity against MRSA; DU644 and
DU645 are the most effective analogs with MBC99 achieved at 0.04 µg mL-1, showing very strong
bactericidal effects. The MBC99 of DU644 was equal to its MIC value toward MRSA, whilst that
of DU645 was twofold higher than its MIC. On the other hand, DU650 possess the weakest
bactericidal activity with MBC99 achieved at 0.16 µg mL-1. In contrast, 99% bactericidal activity
of the regular rifabutin was achieved at 0.1 µg mL-1. Based on these results, DU644 and DU645
showed stronger bactericidal capacity toward MRSA with their MBC values about two times lower
than that of the parent drug.

Figure 8. Bactericidal activity of the lead compounds and the parent drug. This figure displays the bactericidal
activity of DU644 (i), DU645 (ii), DU650 (iii), and rifabutin (iv) in terminating 99% of MRSA.
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Minimum Biofilm Eradication Concentration Assay (MBEC50)

The MBEC50 of our lead rifabutin analogs displayed on Figure 9 and Table 7 represent
their promising antibiofilm activities against MRSA biofilms. DU644 and DU645 are the most
active antibiofilm analogs with MBEC50 achieved at 0.02 µg mL-1; the MBEC50 of DU644 was
twofold lower than its MBC99, whilst that of DU645 was found to be equal its MIC value against
MRSA. In contrast, the MBEC50 of the regular rifabutin was four times higher than those of DU644
and DU645, and was two times lower than that of DU650. The MBEC50 of DU650 achieved at
0.16 µg mL-1 that was equal to its MBC value.

Figure 9. Antibiofilm activity of the lead compounds and the parent drug. This figure displays the antibiofilm
activity of DU644 (i), DU645 (ii), DU650 (iii), and rifabutin (iv) in terminating 50% of MRSA biofilms.

30

Spontaneous Mutation Frequency

The results on Table 8 show that at 5 x MIC, MRSA attained resistance towards all the
lead compounds; however, as the concentration increases, the number of colony decreases. Among
the frontrunner compounds, we found that at 10 x MIC, DU650 was able to significantly reduce
the number of bacterial colonies that grew on plates, producing 238 colonies with a mutation
frequency of 5 x 10-8. Likewise, rifabutin and rifampicin were capable of reducing the number of
bacterial colonies at the concentrarion of 10 x MIC and yielded 580 and 639 mutant colonies with
mutation rates of 6 x 10-8 and 7 x 10-8, respectively. DU645, on the other hand, was active in
reducing the number of MRSA colonies to an enumerable number of 196 and possessed a mutation
rate of 6 x 10-8 at the concentartion of 20 x MIC. In contrast, we noticed that MRSA was swiftly
developed resistance toward DU644, since the compound was not able to reduce the number of
bacterial colonies grown on plates at three lower concentrations (5 x, 10 x and 20 x MIC);
nevertheless, at 50 x MIC we obtained 190 colonies with mutation rate of 7 x 10-8.
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rpoB Mutation Validation

The results of rpoB mutation displayed in Table 9 demonstrate that mutations toward
rifabutin and rifampicin were primarily found at amino acid Histidine-481 of the rpoB gene,
granting high resistance toward these antibiotics and yielding an MIC of > 200 µg mL-1. Moreover,
amino acid substitutions of glutamine at position 465 with a histidine, and of glycine at position
471 and 364 by a cysteine, also conferred high resistance to rifabutin and rifampicin (MIC > 200
µg mL-1), respectively. In contrast, mutational changes toward rifabutin analogs were not located
at amino acid position 481, however, these different mutational locations were also primarily
correlated to high MIC value of > 200 µg mL-1. Point mutational changes of mutant 645 in response
to 20 x MIC of DU645 occurred at two different positions; amino acid substitution of
phenylalanine at position 367 by a valine, and lysine 373 by an asparagine, yielding a remarkable
MIC change from 0.04 µg mL-1 to > 200 µg mL-1. Similarly, point mutational changes displayed
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by mutants of DU650 from 10 x MIC, granted them high resistance toward this compound; mutant
650 #1 possessed an amino acid change at position 352, 408, 417, whilst mutant 650 #2 had one
amino acid change of a tyrosine 443 by a proline, yielding high resistance with MIC of > 200 µg
mL-1 toward DU650.

Cytotoxicity

It is highly important for an antimicrobial agent to have high selectivity toward prokaryotic
cells and therefore will not produce health risk effects in humans. Accordingly, cytotoxicity of
lead rifabutin analogs was performed against HepG2 cells. The potential toxicity screening of these
three lead agents displayed on Figure 10 shows low toxicity. Specifically, DU644 and DU645
demonstrated very low toxicity, allowing for > 75% HepG2 cell recovery at the concentration
ranging from 1.5 µg mL-1 to 25 µg mL-1. The percentage of cells recovered by DU644, DU645,
and rifabutin (positive control) at the concentrations ranging from 1.5 µg mL-1 to 6 µg mL-1 were
quite similar: at 1.5 µg mL-1 to 3 µg mL-1, DU644 and rifabutin produced about 82% cell recovery,
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except for DU644 that produced a slightly increased percent recovery of around 90% at 3 µg mL1

. HepG2 cell recovery decreased as the concentration of the compounds increased; At 6 µg mL-1,

DU645 and rifabutin recovered 78% and 79% cell viability; whilst DU644 allowed for 88% cell
recovery. For DU644 and DU645, we discerned > 76% cell recovery at 12 µg mL-1 and 25 µg mL1

; in contrast, rifabutin was only able to recover < 70% cell viability. However, when the

concentration was increased to 50 µg mL-1, the percent recovery for DU644 and DU645 declined
to 36% and 34%, respectively. In contrast, rifabutin was able to recover 57% of the Hepg2 cell at
the concentration of 50 µg mL-1. Among all the lead agents, DU650 was the least favorable one,
since it recovered < 65% of the HepG2 cells at the concentration ranging from 1.5 to 25 µg mL-1,
and < 30% cell viability at the concentration of 50 µg mL-1. The data from this experiment were
further used to assess the lethal dose (LD50), the concentration of the compound that kills 50% of
the cell lines. The LD50 of DU644, DU645, and DU650 were discerned at the concentration of 43
µg mL-1, 40 µg mL-1, and 32 µg mL-1, respectively.
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Chapter Four: Discussion

Figure 11. Chemical structures of the lead compounds. This figure displays the chemical structures of the
chemical structures of the DU644 (i), DU645 (ii), and DU650 (iii) which possess different halogen substituent on
the spiropiperidyl ring.

The results of antibacterial screening on rifabutin analogs against the ESKAPE pathogens
observed through the MIC assessment revealed their high specificity toward MRSA. Typically,
modification at the spiropiperidyl ring increases the activity of rifamycins antibiotic toward Gram
positive bacteria, especially, S. aureus and M. tuberculosis more than toward Gram negative
species (Sanfilippo et al., 1980). Moreover, two of our lead analogs (DU644 and DU645) possess
increased inhibitory, bactericidal and antibiofilm activities against MRSA when compared to the
parent rifabutin. The increased antibacterial activities of rifabutin analogs occur as a result of drug
modifications at C-3 and C-4 positions of spiropiperidyl ring carrying aromatic rings substituted
with halogens (Figure 11) with which DU644 and DU645 possess bromine (Br) substituent, whilst
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DU650 has iodine (I). The role of halogen substituents in increasing antibacterial activities of a
compound has been well documented. A study by Lu et al. (2001) informs the role of bromine
substituent in enhancing the inhibitory and bactericidal activities of fluoroquinolone antibiotic
against resistant Mycobacterium smegmatis and S. aureus; whilst that of Bahrin et al. (2016) shows
the effectiveness of halogen substituents such as bromine and iodine in increasing bioactivity of
flavonoid compound against Escherichia coli and S. aureus.
From our study, the highest inhibitory activity of rifabutin analogs (DU644 and DU645)
was observed at 0.02 µg mL-1 and 0.04 µg mL-1, respectively; the highest inhibitory activity of the
parent drug toward MRSA was observed at 0.05 µg mL-1. Moreover, our rifabutin analogs possess
a high degree of specificity toward MRSA, compared to the parental drugs that showed inhibition
against Gram-negatives of the ESKAPE pathogens at a concentration exceeding 3 µg mL-1. The
increased antibacterial effectivity of rifamycin analogs toward MRSA confirmed findings of
Sanfilippo et al. (1980), where linear aliphatic chains substituents at N position of the
spiropiperidyl ring increased the activity of rifabutin analogs against S. aureus and M. tuberculosis,
yet decreased their effectivity against Escherichia coli. This presumably related to the increase of
lipophilicity of the compounds (Sanfilippo et al.,1980). Therefore, structural drug modifications
of rifabutin enhance the antibacterial activity of the drug toward MRSA.
In addition to their increased inhibitory activities against MRSA, our lead agents DU644
and DU645 are also more bactericidal toward MRSA than is the parental drug. During the course
of MBC assay, 99% bactericidal activities of DU644 and DU645 were achieved at 0.04 µg mL-1.
However, the highest bactericidal activity of rifabutin was achieved at 0.1 µg mL-1. This indicates
structural drug modification on rifabutin is beneficial in increasing its bactericidal activity against
MRSA.
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Biofilm has been characterized as a virulence factor of Staphylococcus aureus, contributing
to its ability to resist therapeutic intervention (Ohadian et al. 2014). During the course of our
research in assessing antibiofilm activity of the lead rifabutin analogs, we found their potential
antibiofilm abilities in eradicating MRSA biofilms. Importantly, two of our three lead compounds,
DU644, and DU645, were able to clear 50% of MRSA biofilm at a concentration of 0.02 µg mL1

, whilst the 50% biofilm activity of the regular rifabutin occurred at 0.08 µg mL-1. This suggests

that DU644 and DU645 possess more antibiofilm activity than the parental drug. In addition to
this, DU644 and DU645 possess similar bactericidal and antibiofilm activities against MRSA; this
occurred as a result of the same halogen substituent, bromine, they have on the aromatic rings that
attached to the spiropiperidyl ring. Moreover, it is well known that rifabutin possesses good tissue
penetration, is able to penetrate into polymorphonuclear leukocytes, lymphocytes, and
macrophages (Kunin, 1996), and is also active against M. tuberculosis that is difficult to treat with
other antibiotics (Moraes et al., 2015). Therefore, structural drug modifications on rifabutin
increase its activity in penetrating and clearing MRSA biofilms. These results propose rifabutin
analogs as potent antibiofilm drug candidates against MRSA biofilm formation.
During the course of spontaneous mutation assessment we determined that MRSA
spontaneously mutated toward our lead agents and the rifamycin members (rifabutin, and
rifampicin). From this assay, we found MRSA developed resistance toward our lead compounds
at their lowest tested concentration. However, as the concentration of the compounds increased,
the number of colonies arising on plates decreased. At the concentrations higher than 5 x MIC, the
lead agents were able to reduce the number of MRSA that grew on plates and to yield resistance
frequencies of 10-8 per nucleotide per reproduction cycle. This result was in line with previous
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studies, with which the mutation rate of S. aureus toward rifamycins usually are obtained at 10-7
to 10-8 (Aubry-Damon, Soussy, and Courvalin, 1998; Morrow and Harmon, 1979).
The survival of each mutant against high concentrations of the lead agents and of the
rifamycin members (rifabutin and rifampicin) indicated the occurrence of the mutations within the
rpoB gene that encodes the target of rifamycin. The results of rpoB mutation validation assay
affirm that the nucleotide changes led to the amino acid replacement within the RpoB protein of
the rifabutin analogs and rifamycin mutants, and conferred high resistance toward these
compounds. The RpoB protein point mutational changes of the rifabutin and rifampicin mutants
were primarily found at the amino acid histidine position 481; of these mutations, three histidine
481 were replaced by an asparagine, a tyrosine, and an aspartic acid. These amino acid
substitutions granted MRSA a robust resistance against rifabutin and rifampicin, increasing their
MICs from 0.05 µg mL-1 and 0.06 µg mL-1 to > 200 µg mL-1. There is mounting evidence
suggesting the pivotal role of Histidine 481 in conferring high resistance of Staphylococcus aureus
toward rifamycin members (Yu, 2005;, Wichelhaus et al., 1999; Aubry-Damon, Soussy, and
Courvalin, 1998). In addition, the other different positions and types of amino acid alterations were
also found in Rifabutin #2 and Rifampicin #2 mutants: the replacement of glutamine 465 by a
histidine and of glycine 471 and 364 by a cysteine had conferred high resistance for the mutants
against rifabutin and rifampicin, respectively. Moreover, protein sequencing analysis utilizing
Pfam data base revealed the location of amino acid substitution of position 465, 471, and 481 lie
on the catalytic region; whilst that at position 364 was located at the protrusion region. In contrast,
seven point mutational changes of the rifabutin analog mutants were not located at the catalytic
region of the rpoB protein, but were all found at the protrusion region. The amino acids substitution
at position 367 and at 373 of mutant 645, at positions 352, 408, 417, and 442 of mutant 650 #1,
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and at position 443 of mutant 650 #2, had also granted MRSA a robust resistance against DU645
and DU650, yielding to an MIC of > 200 µg mL-1. Point mutational changes at the catalytic and
the protrusion regions of the rpoB protein potentially alter the conformation of the RNA
polymerase binding site and weaken its affinity toward rifampicin (Alifano et al., 2015). From
these results we confirmed that our lead agents performed the same mechanism of action as
rifabutin and rifampicin through interference with the beta-subunit of RNA polymerase.
Toxicity potential of rifabutin is worrisome, since some pharmacokinetic studies reported
its adverse health effects in humans when not used in a proper dosage or when combined with
other drugs. Studies by Zhang et al. (2011) revealed rifabutin administration led to skin rash when
used as a single treatment, caused neutropenia and increased liver enzyme when used in
combination with antiretroviral drugs for TB treatment in HIV/AIDS patients. Therefore, it is
important to assess the potential cytotoxicity of our lead agents. The results of the cytotoxicity
testing we performed suggest rifabutin analogs possess a negligible toxicity when their
concentration was increased from 25 µg mL-1 to 50 µg mL-1. Moreover the 50% killing activities
(LD50) of DU644, DU645, and DU650 were achieved at 43 µg mL-1, 40 µg mL-1, and 32 µg mL1

, respectively. In contrast, the LD50 of the regular rifabutin was not determined during the assay;

however at the highest tested concentration (50 µg mL-1), rifabutin allowed for 57% cell recovery.
From in vitro cytotoxicity results, we revealed our rifabutin analogs possessed a low level of
toxicity when compared to the parent drug.

39

Chapter Five: Conclusions

Strengths and Limitations
Strengths of this study are as follows. The antibacterial activities, target mutation
validation, spontaneous mutation and cytotoxicity assessments performed in our study were
straight forward, easy to prepare, and reproducible. The study was performed in an established
laboratory under the direction of a seasoned scientist and researchers. Moreover, these assessments
were based off well-established techniques for drug discovery. In addition, the findings of this
study are consistent with the findings of the earlier studies performed on ciprofloxacin (Cormier
et al., 2012), rifabutin analogs (Turos et al., 2002), and beta lactam analogs (Sanfilippo et al.,
1980) toward resistant bacteria.
Limitations of this study include incomplete drug characterizations for ciprofloxacin
analogs and beta-lactam analogs due to shortcomings of time and amount of compounds we had
during the course of this research. I have to graduate on summer 2016 and this does not give me
enough time to complete my research on these two class of analogs. Moreover, we ran out of the
active ciprofloxacin and beta lactam analogs after we finished performing the MIC assessments
for these analogs.

Future Directions
As a potential drug for MRSA infections, it is important to perform in vivo assessments for
rifabutin analogs and to optimize their antibacterial capacity through the investigation of
40

substituents at C-3, C-4, or N position of the spiropiperidyl ring that may help to decrease MRSA
resistance towards these drugs. In addition, it is also important to perform bactericidal and
antibiofilm assessments for ciprofloxacin and beta-lactam analogs; therefore, the aim of
determining the efficacy of these analogs toward the ESKAPE pathogens can be fulfilled.

Implications
Infections by the ESKAPE pathogens are still problematic for their growing resistance
towards a wide range of antibiotics and for the decline of antibiotic approval to solve these
problems (Boucher et al., 2009). Among these resistant pathogens, MRSA is the leading cause of
nosocomial infections and has led to higher mortality rate compared to those led by HIV/AIDS
and tuberculosis (Boucher and Corey, 2008). MRSA causes up to 80,461 of nosocomial infections
and kills up to 11, 285 of hospitalized patients in the USA every year (CDC, 2013). Moreover, this
bacterium is medically important in causing prosthetic device-related infection due to its ability to
form biofilms that are almost impossible to clear by immune system and antibiotics (Song et al.,
2013). In addition, it also strikes individuals with healthy immune system, primarily causing skin
and soft tissue infections (SSTIs) (Stryjewski and Chambers, 2008). Accordingly, MRSA becomes
a pivotal public health problem to be resolved. In conclusion, the results of anti-MRSA activities
of our rifabutin analogs, particularly their potent antibiofilm activities, are very promising.
Therefore, as a potent antibacterial agent against MRSA, further development and application of
these compounds might be beneficial for medical use to combat MRSA infections.
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